A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone; Doxorubicin liposomal
- Indications Multiple myeloma
- Focus Therapeutic Use
- 12 Jan 2017 Planned End Date changed from 1 Nov 2017 to 1 Mar 2020.
- 12 Jan 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Sep 2018.
- 12 Jan 2017 Status changed from recruiting to active, no longer recruiting.